ArticleAnnals of surgical oncology2026
Long-term Outcomes After Resection of Solitary Colorectal Liver Metastases.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to characterize the outcomes of patients undergoing resection of solitary colorectal liver metastases (CLM), including patterns of recurrence and usage of salvage therapy.
methodsA retrospective analysis of 535 consecutive patients who underwent resection of solitary CLM between 1999 and 2021 was performed from an institutional database. Extrahepatic disease and prior liver-directed therapy were excluded. Salvage therapy consisted of repeat resection, ablation, or radiation of all sites of recurrence. Outcomes, overall survival (OS), recurrence-free survival, and hepatic recurrence-free survival were analyzed using time-to-event methods.
resultsThe median OS of the whole cohort was 10 years. At a median follow-up of 8.6 years, 52% had recurred at 3 years, 73% of which were at a single site. Salvage therapy was performed in 51% of recurrences and associated with prolonged OS (5.89 [95% confidence interval (CI) 4.68-6.64] years vs. 2.24 [95% CI 1.92-2.41] years; p<0.001). Of those who received salvage therapy, 58% were alive 5 years after recurrence. On multivariate analysis, worse OS was associated with more than three positive lymph nodes in the colon primary (hazard ratio [HR] 2.19 [95% CI 1.56-3.08], p<0.001), tumor size (HR 1.07 [95% CI 1.04-1.1]; p<0.001), and positive margins (HR 1.90 [95% CI 1.07-3.37]; p=0.028). Use of adjuvant hepatic artery infusion chemotherapy was associated with improved OS (HR 0.74 [95% CI 0.54-0.99]; p=0.043) and reduced liver recurrence (HR 0.53 [95% CI 0.37-0.76]; p<0.001).
conclusionsPatients with resected solitary CLM have excellent long-term survival, with half remaining free of recurrence after initial surgery. In the event of recurrence, repeat salvage treatment is feasible and associated with improved survival.
Indexed as
Identifiers
42360648What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.